Let's talk medical research

One in five adults in the U.S. experience a mental health condition each year. Of those, only 43.3% received treatment last year. This World Mental Health Day, we’re highlighting the importance of both awareness and treatment for the millions of people struggling with symptoms.

We’re gearing up to head to Florida later this week for the SCRS Site Solutions Summit, the annual meeting that brings sites, sponsors, CROs, and regulators together to discuss the current state of clinical research and where we go from here. We’re looking forward to meeting some of the brightest in the business, and sharing best practices that can drive success for all.

Of all of the elements of a clinical trial, optimizing patient recruitment may make the most significant impact on trial timelines. Even if you're meeting your recruitment goals – a rare accomplishment, to say the least – trials and budgets always benefit from better efficiency.

Keith Lovell joined Antidote as CFO in September 2015, bringing more than 25 years of financial and commercial experience at companies ranging from major blue chip organizations to startups. Prior to Antidote, he was employee number 30 at Shazam, and helped build it up to a billion dollar valuation.

The Scrip Awards are where the industry’s best and brightest are recognized for excellence across the drug development spectrum. That’s why we’re absolutely honored to announce that Antidote has been named a Scrip Awards finalist in the category of “Best Technological Development in Clinical Trials.” We’ve been a finalist in this category before, and are thrilled that the evolution of our ...

A few years ago, we wrote a blog series for ACRP in which we focused on patient centricity in clinical trial design, recruitment, and execution. Over the next few months, we’ll be taking a second look at those blog posts, sharing updated versions on our own blog. Here’s an update to the second in that series.

Clinical research organizations sometimes create surveys and share general statistics about clinical trial participation. But every patient is different, and overarching stats don't tell the full story.

Today, nearly 60 million patients are needed for currently recruiting clinical trials. And in fact, 80% of trials will be delayed or closed due to difficulty finding patients to take part.

As medications become more targeted and sophisticated, the growing complexity of clinical trial protocols is making it more difficult than ever to find the perfect patients for your trials. That’s why a thoughtful and strategic patient recruitment strategy is key.

While approximately 15 to 20 percent of people 65+ have Mild Cognitive Impairment (MCI), it can be difficult to identify, and difficult to determine if it is related to Alzheimer’s disease. MCI does not always lead to dementia, but people with MCI are four times more likely to develop Alzheimer’s disease and other forms of dementia than those without it — so it’s important to treat this condition ...